Sharma Anish, Kapur Sahil, Kancharla Priyal, Yang Tao
Center for Hypertension and Precision Medicine, Microbiome Consortium, Department of Physiology and Pharmacology, University of Toledo College of Medicine and Life Sciences, OH, USA.
Center for Hypertension and Precision Medicine, Microbiome Consortium, Department of Physiology and Pharmacology, University of Toledo College of Medicine and Life Sciences, OH, USA.
Eur J Pharmacol. 2025 Jan 15;987:177183. doi: 10.1016/j.ejphar.2024.177183. Epub 2024 Dec 6.
The intricate ecosystem of the gut microbiome exhibits sex-specific differences, influencing the susceptibility to cardiovascular diseases (CVD). Imbalance within the gut microbiome compromises the gut barrier, activates inflammatory pathways, and alters the production of metabolites, all of which initiate chronic diseases including CVD. In particular, the interplay between lifestyle choices, hormonal changes, and metabolic byproducts uniquely affects sex-specific gut microbiomes, potentially shaping the risk profiles for hypertension and CVD differently in men and women. Understanding the gut microbiome's role in CVD risk offers informative reasoning behind the importance of developing tailored preventative strategies based on sex-specific differences in CVD risk. Furthermore, insight into the differential impact of social determinants and biological factors on CVD susceptibility emphasizes the necessity for more nuanced approaches. This review also outlines specific dietary interventions that may enhance gut microbiome health, offering a glimpse into potential therapeutic avenues for reducing CVD risk that require greater awareness. Imbalance in natural gut microbiomes may explain etiologies of chronic diseases; we advocate for future application to alter the gut microbiome as possible treatment of the aforementioned diseases. This review mentions the idea of altering the gut microbiome through interventions such as fecal microbiota transplantation (FMT), a major application of microbiome-based therapy that is first-line for Clostridium difficile infections and patient-specific probiotics highlights more innovative approaches to hypertension and CVD prevention. Through increased analysis of gut microbiota compositions along with patient-centric probiotics and microbiome transfers, this review advocates for future preventative strategies for hypertension.
肠道微生物群的复杂生态系统存在性别特异性差异,影响心血管疾病(CVD)的易感性。肠道微生物群的失衡会损害肠道屏障、激活炎症途径并改变代谢产物的产生,所有这些都会引发包括CVD在内的慢性疾病。特别是,生活方式选择、激素变化和代谢副产物之间的相互作用独特地影响着性别特异性肠道微生物群,可能会使男性和女性患高血压和CVD的风险状况有所不同。了解肠道微生物群在CVD风险中的作用,为基于CVD风险的性别特异性差异制定量身定制的预防策略的重要性提供了有益的依据。此外,深入了解社会决定因素和生物因素对CVD易感性的不同影响,强调了采用更细致入微方法的必要性。本综述还概述了可能改善肠道微生物群健康的特定饮食干预措施,让人们得以一瞥降低CVD风险的潜在治疗途径,而这需要更多的关注。天然肠道微生物群的失衡可能解释慢性疾病的病因;我们主张未来将改变肠道微生物群作为上述疾病的可能治疗方法。本综述提到了通过粪便微生物群移植(FMT)等干预措施改变肠道微生物群的想法,这是基于微生物群的治疗的主要应用,是艰难梭菌感染的一线治疗方法,而患者特异性益生菌则突出了预防高血压和CVD的更具创新性的方法。通过增加对肠道微生物群组成的分析以及以患者为中心的益生菌和微生物群转移,本综述倡导未来预防高血压的策略。